GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » InnovAge Holding Corp (NAS:INNV) » Definitions » ROE %

InnovAge Holding (InnovAge Holding) ROE % : -4.82% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is InnovAge Holding ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. InnovAge Holding's annualized net income for the quarter that ended in Dec. 2023 was $-13.8 Mil. InnovAge Holding's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $286.4 Mil. Therefore, InnovAge Holding's annualized ROE % for the quarter that ended in Dec. 2023 was -4.82%.

The historical rank and industry rank for InnovAge Holding's ROE % or its related term are showing as below:

INNV' s ROE % Range Over the Past 10 Years
Min: -20.2   Med: -1.96   Max: 30
Current: -10.61

During the past 5 years, InnovAge Holding's highest ROE % was 30.00%. The lowest was -20.20%. And the median was -1.96%.

INNV's ROE % is ranked worse than
72.55% of 612 companies
in the Healthcare Providers & Services industry
Industry Median: 4.115 vs INNV: -10.61

InnovAge Holding ROE % Historical Data

The historical data trend for InnovAge Holding's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnovAge Holding ROE % Chart

InnovAge Holding Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23
ROE %
26.39 30.00 -20.20 -1.96 -12.94

InnovAge Holding Quarterly Data
Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.39 -8.58 -14.84 -14.13 -4.82

Competitive Comparison of InnovAge Holding's ROE %

For the Medical Care Facilities subindustry, InnovAge Holding's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnovAge Holding's ROE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, InnovAge Holding's ROE % distribution charts can be found below:

* The bar in red indicates where InnovAge Holding's ROE % falls into.



InnovAge Holding ROE % Calculation

InnovAge Holding's annualized ROE % for the fiscal year that ended in Jun. 2023 is calculated as

ROE %=Net Income (A: Jun. 2023 )/( (Total Stockholders Equity (A: Jun. 2022 )+Total Stockholders Equity (A: Jun. 2023 ))/ count )
=-40.673/( (332.364+296.299)/ 2 )
=-40.673/314.3315
=-12.94 %

InnovAge Holding's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-13.788/( (287.204+285.503)/ 2 )
=-13.788/286.3535
=-4.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


InnovAge Holding  (NAS:INNV) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-13.788/286.3535
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-13.788 / 755.592)*(755.592 / 539.928)*(539.928 / 286.3535)
=Net Margin %*Asset Turnover*Equity Multiplier
=-1.82 %*1.3994*1.8855
=ROA %*Equity Multiplier
=-2.55 %*1.8855
=-4.82 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-13.788/286.3535
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-13.788 / -14.912) * (-14.912 / -7.14) * (-7.14 / 755.592) * (755.592 / 539.928) * (539.928 / 286.3535)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9246 * 2.0885 * -0.94 % * 1.3994 * 1.8855
=-4.82 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


InnovAge Holding ROE % Related Terms

Thank you for viewing the detailed overview of InnovAge Holding's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


InnovAge Holding (InnovAge Holding) Business Description

Traded in Other Exchanges
N/A
Address
8950 East Lowry Boulevard, Denver, CO, USA, 80230
InnovAge Holding Corp is a healthcare delivery platform by several participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Its patient-centered care delivery approach improves the quality of care while keeping them in their homes and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. The company's segment includes PACE and others. It generates maximum revenue from the PACE segment.
Executives
Teresa Sparks director 40 BURTON HILLS BOULEVARD SUITE 500, NASHVILLE TN 37215
Nicole Damato officer: CHIEF LEGAL OFFICER 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Benjamin C Adams officer: CHIEF FINANCIAL OFFICER 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Patricia Fontneau director 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Christine Bent officer: CHIEF OPERATIONS OFFICER 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Thomas Scully director 320 PARK AVENUE, SUITE # 2500, NEW YORK NM 10022
Richard Feifer officer: CHIEF MEDICAL OFFICER C/O GENESIS HEALTHCARE, INC., 101 EAST STATE STREET, KENNETT SQUARE PA 19348
James G Carlson director 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Patrick T Blair officer: PRESIDENT 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Caroline Dechert director 580 CALIFORNIA ST., SUITE 1700, SAN FRANCISCO CA 94104
Pavithra Mahesh director 601 LEXINGTON AVE., 53RD FLOOR, NEW YORK NY 10022
Maureen Hewitt director, officer: CEO, President and Director 8950 E. LOWRY BLVD., DENVER CO 80230
Maria Lozzano officer: CORPORATE COO 8950 E. LOWRY BLVD., DENVER CO 80230
Robin Doerr officer: CHIEF SALES AND MKTG. OFFICER 8950 E. LOWRY BLVD., DENVER CO 80230
Melissa Welch officer: CHIEF MEDICAL OFFICER 8950 E. LOWRY BLVD., DENVER CO 80230